# Wockhardt Ltd 獲准在印度銷售其創新抗生素 Zaynich。

*biotech · news · 2026-05-28 · Devdiscourse*

## Key points

- Wockhardt Ltd 獲得 CDSCO 批准，在印度銷售用於重度尿道感染的 Zaynich。
- Zaynich 結合 Zidebactam 與 Cefepime，針對包括革蘭氏陰性菌血症在內的複雜尿道感染。
- ENHANCE-1 第三期臨床試驗顯示 Zaynich 的療效與美羅培南相當。
- 第一及第二期研究報告 Zaynich 在重度感染中臨床成功率超過 97%。

Wockhardt Ltd has been granted approval to market its innovative antibiotic, Zaynich, in India, the company announced on Thursday. This decision by the Central Drugs Standard Control Organisation (CDSCO) allows the pharmaceutical firm to introduce its treatment aimed at severe urinary tract infections (UTIs) in adult patients. Zaynich combines Zidebactam and Cefepime, targeting complex UTIs including pyelonephritis and infections that lead to Gram-negative bacteremia. This significant step follows the completion of the ENHANCE-1 Phase 3 global clinical trial, which demonstrated Zaynich's efficacy compared to meropenem, a standard treatment for such bacterial infections. Additionally, extensive testing including Phase 1 and Phase 2 studies showcased over 97% clinical success against various severe infections like hospital-acquired bacterial pneumonia. Wockhardt highlights Zaynich as a potentially crucial therapeutic option amidst rising antibiotic resistance in India. (With inputs from agencies.)

**Companies:** Wockhardt Ltd
**Countries:** India

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3924674-wockhardt-secures-approval-for-uti-drug-launch-in-india)

---

Canonical: https://newsio.io/zh-TW/n/a3d19eee-d434-4f57-a279-5c3e54597a81/wockhardt-ltd-zaynichcdsco
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works